This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: TRA-2P

March 2012 Br J Cardiol 2012;19:10

TRA-2P: new antiplatelet drug reduces CV events but ups bleeding

News from the world of cardiology

Abstract

Vorapaxar is a protease-activated receptor 1 (PAR-1) antagonist that blocks thrombin-induced platelet activation and therefore inhibits platelets by a different mechanism to other available antiplatelet drugs. The TRA-2P study involved 26,449 patients with myocardial infarction (MI), ischaemic stroke, or peripheral vascular disease. Addition of vorapaxar to standard of care is reported to have significantly reduced the risk of cardiovascular death/MI/stroke/urgent coronary revascularisation (composite primary end point), but at the cost of increased bleeding. However, there was a lower risk of intracranial haemorrhage in patients without a hi

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now